Some evidence has demonstrated that combining anti-IL-17A antibodies with gemcitabine represents an effective approach to enhancing the antitumor response by modulating macrophages, particularly in pancreatic cancer, for which gemcitabine is currently the most widely used anticancer drug [15]. The gene discussed is IL17A; the disease is familial pancreatic carcinoma.